Futura Medical (FUM) Competitors

In the previous week, Futura Medical had 5 more articles in the media than BiVictriX Therapeutics. MarketBeat recorded 5 mentions for Futura Medical and 0 mentions for BiVictriX Therapeutics. BiVictriX Therapeutics' average media sentiment score of 0.00 beat Futura Medical's score of -0.32 indicating that BiVictriX Therapeutics is being referred to more favorably in the news media.

BiVictriX Therapeutics has lower revenue, but higher earnings than Futura Medical. Futura Medical is trading at a lower price-to-earnings ratio than BiVictriX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Futura Medical has a beta of 0.021, suggesting that its share price is 98% less volatile than the broader market. Comparatively, BiVictriX Therapeutics has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market.

BiVictriX Therapeutics has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. BiVictriX Therapeutics' return on equity of -103.99% beat Futura Medical's return on equity.

1.0% of Futura Medical shares are owned by institutional investors. Comparatively, 30.8% of BiVictriX Therapeutics shares are owned by institutional investors. 16.0% of Futura Medical shares are owned by company insiders. Comparatively, 42.6% of BiVictriX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Futura Medical had 4 more articles in the media than Oxford BioDynamics. MarketBeat recorded 5 mentions for Futura Medical and 1 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.00 beat Futura Medical's score of -0.32 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Futura Medical has a beta of 0.021, suggesting that its share price is 98% less volatile than the broader market.

Futura Medical has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.

Futura Medical has a net margin of -534.62% compared to Oxford BioDynamics' net margin of -825.61%. Futura Medical's return on equity of -310.00% beat Oxford BioDynamics' return on equity.

11.6% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 1.0% of Futura Medical shares are held by institutional investors. 15.6% of Oxford BioDynamics shares are held by company insiders. Comparatively, 16.0% of Futura Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nuformix has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. Nuformix's return on equity of -83.53% beat Futura Medical's return on equity.

1.0% of Futura Medical shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 16.0% of Futura Medical shares are owned by company insiders. Comparatively, 7.5% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuformix has lower revenue, but higher earnings than Futura Medical. Nuformix is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.

Futura Medical has a beta of 0.021, meaning that its share price is 98% less volatile than the broader market. Comparatively, Nuformix has a beta of 1.519, meaning that its share price is 52% more volatile than the broader market.

In the previous week, Futura Medical had 5 more articles in the media than Nuformix. MarketBeat recorded 5 mentions for Futura Medical and 0 mentions for Nuformix. Nuformix's average media sentiment score of 0.00 beat Futura Medical's score of -0.32 indicating that Nuformix is being referred to more favorably in the news media.

1.0% of Futura Medical shares are owned by institutional investors. Comparatively, 1.4% of Talisman Metals shares are owned by institutional investors. 16.0% of Futura Medical shares are owned by insiders. Comparatively, 95.2% of Talisman Metals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Talisman Metals has lower revenue, but higher earnings than Futura Medical. Futura Medical is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

Talisman Metals has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. Talisman Metals' return on equity of -32.71% beat Futura Medical's return on equity.

Futura Medical has a beta of 0.021, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Talisman Metals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

In the previous week, Futura Medical had 5 more articles in the media than Talisman Metals. MarketBeat recorded 5 mentions for Futura Medical and 0 mentions for Talisman Metals. Talisman Metals' average media sentiment score of 0.00 beat Futura Medical's score of -0.32 indicating that Talisman Metals is being referred to more favorably in the news media.